A platform for research: civil engineering, architecture and urbanism
A platform for research: civil engineering, architecture and urbanism
Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box
A tumour biomarker is a characteristic that is objectively measured and evaluated in tumour samples as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. The development of a biomarker contemplates distinct phases, including discovery by hypothesis-generating preclinical or exploratory studies, development and qualification of the assay for the identification of the biomarker in clinical samples, and validation of its clinical significance. Although guidelines for the development and validation of biomarkers are available, their implementation is challenging, owing to the diversity of biomarkers being developed. The term 'validation' undoubtedly has several meanings; however, in the context of biomarker research, a test may be considered valid if it is 'fit for purpose'. In the process of validation of a biomarker assay, a key point is the validation of the methodology. Here we discuss the challenges for the technical validation of immunohistochemical and gene expression assays to detect tumour biomarkers and provide suggestions of pragmatic solutions to address these challenges.
Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box
A tumour biomarker is a characteristic that is objectively measured and evaluated in tumour samples as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. The development of a biomarker contemplates distinct phases, including discovery by hypothesis-generating preclinical or exploratory studies, development and qualification of the assay for the identification of the biomarker in clinical samples, and validation of its clinical significance. Although guidelines for the development and validation of biomarkers are available, their implementation is challenging, owing to the diversity of biomarkers being developed. The term 'validation' undoubtedly has several meanings; however, in the context of biomarker research, a test may be considered valid if it is 'fit for purpose'. In the process of validation of a biomarker assay, a key point is the validation of the methodology. Here we discuss the challenges for the technical validation of immunohistochemical and gene expression assays to detect tumour biomarkers and provide suggestions of pragmatic solutions to address these challenges.
Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box
C. Marchiò (author) / M. Dowsett (author) / J.S. Reis Filho (author)
2011-01-01
Article (Journal)
Electronic Resource
English
DDC:
690
| Taylor & Francis Verlag | 1959
Economic loss: Closing Pandora's Box?
| Emerald Group Publishing | 1989
Pandora's seed : the unforeseen cost of civilization
| Catalogue agriculture | 2010
Opening Pandora's box A look at insulation solutions
British Library Online Contents | 2002